Expertise in
8
conditions

Min-hee S. Ryu

Seoul, KR 
Expertise in
8
conditions
Seoul, KR 

Overview

Min-hee Ryu practices practicing medicine in Seoul, Republic of Korea.

Ryu is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Stomach Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumor, Gastrectomy, and Stent Placement.

They are actively involved in clinical research, co-authoring 327 peer reviewed articles and participating in 5 clinical trials.

Locations

Seoul, Republic of Korea
Other Locations
Daegu, Republic of Korea
Ulsan, Republic of Korea
Kwonoh Park, Gyeongsangnam Do 50612, Busan, Republic of Korea
Jeonju, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drug: Durvalumab+Tremelimumab+Paclitaxel
Study Phase: Phase 1/Phase 2
Randomized Phase 2 Study of Intermittent vs Continuous Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors (GISTs)
Randomized Phase 2 Study of Intermittent vs Continuous Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors (GISTs)
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drug: Imatinib Mesylate
Study Phase: Phase 2
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Enrollment Status: Terminated
Publish Date: April 11, 2022
Intervention Type: Drug
Study Drugs: Rivoceranib, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
View 4 Less Clinical Trials

327 Total Publications

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
Journal: Journal for immunotherapy of cancer
Published: August 03, 2026

Frequently Asked Questions about Min-hee S. Ryu

Is Min-hee S. Ryu a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Min-hee S. Ryu is classified as an Distinguished expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Min-hee S. Ryu participate in research or clinical trials?

Yes. Min-hee S. Ryu has published 327 articles and abstracts on conditions like Stomach Cancer. You can view a list of Min-hee S. Ryu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ryu's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile